Ruchi is a financial writer covering the US stock market. She is located in New Zealand but has been following and analyzing American public companies for more than 15 years. Previously, she worked at Businessday Nigeria and has written content for MarketRealist, Benzinga and Zacks Investment Research among others.
This longtime Buffett holding is down about 15% since setting its all-time highs in September, and looks like a bargain buy in this market.
/Microsoft%20Corporation%20logo%20on%20sign-by%20Jean-Luc%20Ichard%20via%20iStock.jpg)
MSFT has underperformed the markets this year, but analysts still like the stock.
/Happy%20friends%20look%20at%20phone%20by%20Eduard%20Figueres%20via%20iStock.jpg)
This social media cratered 14% in a single day after earnings, but analysts came to its defense.
This breakout stock has nearly doubled this year, and just delivered stellar earnings.
This artificial intelligence growth stock is already up more than 600% this year, and analysts are struggling to keep up with price target hikes.
Traders sold the news on this biotech stock's conference update.
Tilray reported a positive update for its chemo-related drug.
Entergy plans to invest in more nuclear energy capacity, including a new reactor and SMRs.
/Engineer%20in%20Sterile%20Coverall%20Holds%20Microchip%20with%20Gloves%20and%20Examines%20it%20by%20Gorodenkoff%20via%20Shutterstock.jpg)
Breakout semiconductor stock ALAB has more than doubled in just a few months.
This biotech penny stock could more than triple, based on consensus forecasts.
